Immune repertoire and responses to neoadjuvant TCHP therapy in HER2-positive breast cancer.
Jun Young ShinBaknoon HamJeong-Han SeoSae Byul LeeIn Ah ParkGyungyub GongSung-Bae KimHee Jin LeePublished in: Therapeutic advances in medical oncology (2023)
The role of the diversity, richness, and density of the TCR and BCR repertoires as predictive markers for TCHP response was not identified. Compositions of low-frequency clones could be candidates for predictive factors of TCHP response; however, validation studies and further research are necessary.